Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâs product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâs patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

May. 30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
2022	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Capitalization	10.46B 74.3B 9.96B 9.34B 8.28B 14.89B 887B 16.45B 115B 42.48B 365B 39.29B 38.41B 1,607B	P/E ratio 2017	-154x	P/E ratio 2018	-708x
Enterprise value	10.49B 74.51B 9.99B 9.37B 8.31B 14.93B 889B 16.5B 115B 42.6B 366B 39.4B 38.52B 1,611B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	May. 30	CI
Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	22-06-28	CI
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	21-04-25	CI
Veloxis Pharmaceuticals A/S Announces Board Appointments	20-02-17	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	20-02-07	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	20-01-13	CI
Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call	19-11-25
Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	19-11-24	CI
Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019	19-11-13
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	19-10-30	CI

Scandion Oncology A/S : appoints Johnny Stilou as new CFO	21-06-02	AQ
Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	20-02-17	AQ
Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	20-01-29	AQ
Veloxis Pharmaceuticals A/S : - Notice to Convene Extraordinary General Meeting	20-01-27	AQ
Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	20-01-27	AQ

Veloxis Pharmaceuticals A/S Stock

Equities

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Daisuke Matsuo ADM	Chief Administrative Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	2017-09-12
Stacy Wheeler COO	Chief Operating Officer	-	2016-02-29

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK KGAA	-1.40%	+0.86%	+2.58%	-37.13%	65.28B
KYOWA KIRIN CO. LTD.	-1.77%	-1.25%	-1.85%	-24.71%	8.21B
YUHAN CORPORATION	+2.48%	+2.48%	+92.05%	+118.74%	6.12B
HALOZYME THERAPEUTICS, INC.	+0.36%	-0.12%	+19.28%	+39.13%	6.09B
SK BIOPHARMACEUTICALS CO., LTD.	+0.86%	+1.73%	+17.67%	-0.56%	5.75B
BETTA PHARMACEUTICALS CO., LTD.	-0.16%	-1.30%	-7.29%	-33.41%	3.15B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-3.39%	+1.66%	+20.31%	+30.01%	2.34B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.14%	+0.25%	-34.37%	+28.89%	2.05B
SUPERNUS PHARMACEUTICALS, INC.	+0.03%	-2.22%	+36.13%	+25.20%	2B
Average	-0.41%	+1.73%	+16.06%	+16.24%	10.26B
Weighted average by Cap.	-0.92%	+2.46%	+9.53%	-15.74%

	2017	2018
Net sales	30.17M 214M 28.74M 26.95M 23.9M 42.95M 2.56B 47.47M 331M 123M 1.05B 113M 111M 4.64B	39.49M 281M 37.63M 35.28M 31.29M 56.23M 3.35B 62.15M 434M 160M 1.38B 148M 145M 6.07B
Net income	-9.54M -67.81M -9.09M -8.52M -7.56M -13.58M -809M -15.02M -105M -38.77M -333M -35.85M -35.05M -1.47B	-5.28M -37.56M -5.04M -4.72M -4.19M -7.52M -448M -8.32M -58.05M -21.47M -185M -19.86M -19.41M -812M
Net Debt	18.05M 128M 17.2M 16.13M 14.3M 25.7M 1.53B 28.41M 198M 73.34M 631M 67.83M 66.31M 2.77B	29.38M 209M 28M 26.25M 23.28M 41.83M 2.49B 46.24M 323M 119M 1.03B 110M 108M 4.52B